The current and future status of inotropes in heart failure management

References

• Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023 Jan 18;118(17):3272–3287.
   PubMed Web of Science ®Google Scholar
• Kwok CS, Abramov D, Parwani P, et al. Cost of inpatient heart failure care and 30-day readmissions in the United States. Int J Cardiol. 2021 Apr 15;329:115–122.
   PubMed Web of Science ®Google Scholar
• Hessel FP. Overview of the socio-economic consequences of heart failure. Cardiovasc Diagn Ther. 2021 Feb;11(1):254–262. doi: 10.21037/cdt-20-291
   PubMed Web of Science ®Google Scholar
• Maggioni AP, Dahlström U, Filippatos G, et al. Eurobservational research programme: the heart failure pilot survey (ESC-HF Pilot). Eur J Heart Fail. 2010 Oct;12(10):1076–1084.
   PubMed Web of Science ®Google Scholar
• Harjola V-P, Lassus J, Sionis A, et al. Clinical picture and risk prediction of short-term mortality in cardiogenic shock. Eur J Heart Fail. 2015;17(5):501–509. doi: 10.1002/ejhf.260
   PubMed Web of Science ®Google Scholar
• Venkatason P, Zubairi YZ, Ahmad WAW, et al. In-hospital mortality of cardiogenic shock complicating ST-elevation myocardial infarction in Malaysia: a retrospective analysis of the Malaysian National Cardiovascular Database (NCVD) registry. BMJ Open. 2019;9(5):e025734. doi: 10.1136/bmjopen-2018-025734
   PubMed Web of Science ®Google Scholar
• Bistola V, Arfaras-Melainis A, Polyzogopoulou E, et al. Inotropes in acute heart failure: from guidelines to practical use: therapeutic options and clinical practice. Card Fail Rev. 2019 Nov;5(3):133–139.
   PubMedGoogle Scholar
• Bistola V, Chioncel O. Inotropes in acute heart failure. Cont Cardiol Educ. 2017;3(3):107–116. doi: 10.1002/cce2.59
   Google Scholar
• McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 2021 Sep 21;42(36):3599–3726. doi: 10.1093/eurheartj/ehab368
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2022 May 3;145(18):e876–e894.
   PubMed Web of Science ®Google Scholar
• Gustafsson F, Damman K, Nalbantgil S, et al. Inotropic therapy in patients with advanced heart failure. A clinical consensus statement from the heart failure association of the European society of cardiology. Eur J Heart Fail. 2023;25(4):457–468.
   PubMed Web of Science ®Google Scholar
• Nizamic T, Murad MH, Allen Larry A, et al. Ambulatory inotrope infusions in advanced heart failure. JACC Heart Fail. 2018 2018 Sep 1;6(9):757–767. doi: 10.1016/j.jchf.2018.03.019
   PubMed Web of Science ®Google Scholar
• Tisdale JE, Patel R, Webb CR, et al. Electrophysiologic and proarrhythmic effects of intravenous inotropic agents. Prog Cardiovasc Dis. 1995 Sep;38(2):167–180.
   PubMed Web of Science ®Google Scholar
• Overgaard CB, Dzavík V. Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease. Circulation. 2008 Sep 2;118(10):1047–1056.
   PubMed Web of Science ®Google Scholar
• Gorski PA, Ceholski DK, Hajjar RJ. Altered myocardial calcium cycling and energetics in heart failure–a rational approach for disease treatment. Cell Metab. 2015 Feb 3;21(2):183–194.
   PubMed Web of Science ®Google Scholar
• Lou Q, Janardhan A, Efimov IR. Remodeling of calcium handling in human heart failure. Adv Exp Med Biol. 2012;740:1145–1174.
   PubMed Web of Science ®Google Scholar
• Yue DT, Marban E, Wier WG. Relationship between force and intracellular [Ca2+] in tetanized mammalian heart muscle. J Gen Physiol. 1986 Feb;87(2):223–242. doi: 10.1085/jgp.87.2.223
   PubMed Web of Science ®Google Scholar
• Antos CL, Frey N, Marx SO, et al. Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase a. Circ Res. 2001 Nov 23;89(11):997–1004.
   PubMed Web of Science ®Google Scholar
• Feldman RD, Gros R. New insights into the regulation of cAMP synthesis beyond GPCR/G protein activation: implications in cardiovascular regulation. Life Sci. 2007 Jul 4;81(4):267–271.
   PubMed Web of Science ®Google Scholar
• O’Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the flolan international randomized survival trial (FIRST). Am Heart J. 1999 1999 Jul 1;138(1):78–86. doi: 10.1016/S0002-8703(99)70250-4
   PubMed Web of Science ®Google Scholar
• Triposkiadis FK, Butler J, Karayannis G, et al. Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: the dopamine in acute decompensated heart failure II (DAD-HF II) trial. Int J Cardiol. 2014 Mar 1;172(1):115–121.
   PubMed Web of Science ®Google Scholar
• Chen HH, Anstrom KJ, Givertz MM, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the rose acute heart failure randomized trial. JAMA. 2013;310(23):2533–2543. doi: 10.1001/jama.2013.282190
   PubMed Web of Science ®Google Scholar
• Cuffe MS, Califf RM, Adams KF Jr., et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002 Mar 27;287(12):1541–1547.
   PubMed Web of Science ®Google Scholar
• Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The promise study research group. N Engl J Med. 1991 Nov 21;325(21):1468–1475.
   PubMed Web of Science ®Google Scholar
• Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002 Jul 20;360(9328):196–202.
   PubMed Web of Science ®Google Scholar
• Moiseyev VS, Põder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002 Sep;23(18):1422–1432.
   PubMed Web of Science ®Google Scholar
• Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007 May 2;297(17):1883–1891.
   PubMed Web of Science ®Google Scholar
• Altenberger J, Parissis JT, Costard-Jaeckle A, et al. Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial. Eur J Heart Fail. 2014 Aug;16(8):898–906.
   PubMed Web of Science ®Google Scholar
• Comín-Colet J, Manito N, Segovia-Cubero J, et al. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial. Eur J Heart Fail. 2018 Jul;20(7):1128–1136.
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Diaz R, Felker GM, et al. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N Engl J Med. 2020;384(2):105–116. doi: 10.1056/NEJMoa2025797
   PubMed Web of Science ®Google Scholar
• Lewis GD, Voors AA, Cohen-Solal A, et al. Effect of omecamtiv mecarbil on exercise capacity in chronic heart failure with reduced ejection fraction: the METEORIC-HF randomized clinical trial. JAMA. 2022;328(3):259–269. doi: 10.1001/jama.2022.11016
   PubMed Web of Science ®Google Scholar
• Shah SJ, Blair JE, Filippatos GS, et al. Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial. Am Heart J. 2009 Jun;157(6):1035–1041.
   PubMed Web of Science ®Google Scholar
• Metra M, Chioncel O, Cotter G, et al. Safety and efficacy of istaroxime in patients with acute heart failure-related pre-cardiogenic shock – a multicentre, randomized, double-blind, placebo-controlled, parallel group study (SEISMiC). Eur J Heart Fail. 2022;24(10):1967–1977. doi: 10.1002/ejhf.2629
   PubMed Web of Science ®Google Scholar
• Kislitsina ON, Rich JD, Wilcox JE, et al. Shock - classification and pathophysiological principles of therapeutics. Curr Cardiol Rev. 2019;15(2):102–113. doi: 10.2174/1573403X15666181212125024
   PubMed Web of Science ®Google Scholar
• Mebazaa A, Combes A, van Diepen S, et al. Management of cardiogenic shock complicating myocardial infarction. Intensive care Med. 2018 Jun;44(6):760–773.
   PubMed Web of Science ®Google Scholar
• Thackray S, Easthaugh J, Freemantle N, et al. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail. 2002 Aug;4(4):515–529.
   PubMed Web of Science ®Google Scholar
• Metra M, Nodari S, D’Aloia A, et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol. 2002 Oct 2;40(7):1248–1258.
   PubMed Web of Science ®Google Scholar
• Tarján J, Nagy L, Liziczai I, et al. Arrhythmic effects of intermittent dobutamine therapy in chronic heart disease failure. The working group of cardiology of the Academic Committee of Veszprém, Hungary. Am J Ther. 1998 Nov;5(6):405–411.
   PubMedGoogle Scholar
• Polyzogopoulou E, Arfaras-Melainis A, Bistola V, et al. Inotropic agents in cardiogenic shock. Curr Opin Crit Care. 2020 Aug;26(4):403–410.
   PubMed Web of Science ®Google Scholar
• Elkayam U, Ng TM, Hatamizadeh P, et al. Renal vasodilatory action of dopamine in patients with heart failure: magnitude of effect and site of action. Circulation. 2008 Jan 15;117(2):200–205.
   PubMed Web of Science ®Google Scholar
• Farmakis D, Agostoni P, Baholli L, et al. A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus. Int J Cardiol. 2019 Dec 15;297:83–90.
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Sumida TS, Nomura S, et al. Cardiac dopamine D1 receptor triggers ventricular arrhythmia in chronic heart failure. Nat Commun. 2020 Aug 31;11(1):4364.
   PubMed Web of Science ®Google Scholar
• Hamzaoui O, Shi R. Early norepinephrine use in septic shock. J Thorac Dis. 2020 Feb;12(Suppl 1):S72–s77. doi: 10.21037/jtd.2019.12.50
   PubMedGoogle Scholar
• Lymperopoulos A, Rengo G, Koch WJ. Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ Res. 2013 Aug 30;113(6):739–753.
   PubMed Web of Science ®Google Scholar
• Levy B, Perez P, Perny J, et al. Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Crit Care Med. 2011 Mar;39(3):450–455.
   PubMed Web of Science ®Google Scholar
• Tarvasmäki T, Lassus J, Varpula M, et al. Current real-life use of vasopressors and inotropes in cardiogenic shock - adrenaline use is associated with excess organ injury and mortality. Crit Care. 2016 Jul 4;20(1):208.
   PubMedGoogle Scholar
• Nativi-Nicolau J, Selzman CH, Fang JC, et al. Pharmacologic therapies for acute cardiogenic shock. Curr Opin Cardiol. 2014 May;29(3):250–257.
   PubMed Web of Science ®Google Scholar
• Lowes BD, Tsvetkova T, Eichhorn EJ, et al. Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol. 2001 Dec;81(2–3):141–149.
   PubMed Web of Science ®Google Scholar
• Felker GM, Benza RL, Chandler AB, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol. 2003 Mar 19;41(6):997–1003.
   PubMed Web of Science ®Google Scholar
• Parissis JT, Andreadou I, Bistola V, et al. Novel biologic mechanisms of levosimendan and its effect on the failing heart. Expert Opin Investig Drugs. 2008 Aug;17(8):1143–1150.
   PubMed Web of Science ®Google Scholar
• Papp Z, Édes I, Fruhwald S, et al. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol. 2012 Aug 23;159(2):82–87.
   PubMed Web of Science ®Google Scholar
• Farmakis D, Alvarez J, Gal TB, et al. Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: An expert panel position paper. Int J Cardiol. 2016 [2016 Nov 1];222:303–312.
   PubMed Web of Science ®Google Scholar
• Antila S, Kivikko M, Lehtonen L, et al. Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan. Br J Clin Pharmacol. 2004 Apr;57(4):412–415.
   PubMed Web of Science ®Google Scholar
• Puttonen J, Kantele S, Kivikko M, et al. Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites. Clin Pharmacokinet. 2007;46(3):235–246. doi: 10.2165/00003088-200746030-00004
   PubMed Web of Science ®Google Scholar
• Cleland JG, Freemantle N, Coletta AP, et al. Clinical trials update from the American heart association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail. 2006 Jan;8(1):105–110.
   PubMed Web of Science ®Google Scholar
• Burkhoff D, Borlaug BA, Shah SJ, et al. Levosimendan improves hemodynamics and exercise tolerance in PH-HFpEF: results of the randomized placebo-controlled HELP trial. JACC Heart Fail. 2021 May;9(5):360–370.
   PubMed Web of Science ®Google Scholar
• Zhang LL, Chen GH, Tang RJ, et al. Levosimendan reverses cardiac malfunction and cardiomyocyte ferroptosis during heart failure with preserved ejection fraction via connexin 43 signaling activation. Cardiovasc Drugs Ther. 2023 Mar 7. doi: 10.1007/s10557-023-07441-4
   Web of Science ®Google Scholar
• Haikala H, Kaivola J, Nissinen E, et al. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol. 1995 1995 Sep 1;27(9):1859–1866. doi: 10.1016/0022-2828(95)90009-8
   PubMed Web of Science ®Google Scholar
• Psotka MA, Gottlieb SS, Francis GS, et al. Cardiac calcitropes, myotropes, and mitotropes: JACC review topic of the week. J Am Coll Cardiol. 2019 2019 May 14;73(18):2345–2353. doi: 10.1016/j.jacc.2019.02.051
   PubMed Web of Science ®Google Scholar
• Malik FI, Hartman JJ, Elias KA, et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science. 2011 Mar 18;331(6023):1439–1443.
   PubMed Web of Science ®Google Scholar
• Cleland JG, Teerlink JR, Senior R, et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet. 2011 Aug 20;378(9792):676–683.
   PubMed Web of Science ®Google Scholar
• Felker GM, Solomon SD, Claggett B, et al. Assessment of omecamtiv mecarbil for the treatment of patients with severe heart failure: a post hoc analysis of data from the GALACTIC-HF randomized clinical trial. JAMA Cardiol. 2022 Jan 1;7(1):26–34.
   PubMed Web of Science ®Google Scholar
• Khan H, Metra M, Blair JEA, et al. Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na–K-ATPase inhibition: a new promising treatment for acute heart failure syndromes? Heart Fail Rev. 2009 2009 Dec 1;14(4):277–287. doi: 10.1007/s10741-009-9136-z
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Blair JE, Filippatos GS, et al. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. J Am Coll Cardiol. 2008 Jun 10;51(23):2276–2285.
   PubMed Web of Science ®Google Scholar
• Levy B, Bastien O, Karim B, et al. Experts’ recommendations for the management of adult patients with cardiogenic shock. Ann Intensive Care. 2015 Dec;5(1):52.
   PubMedGoogle Scholar
• Alla F, Zannad F, Filippatos G. Epidemiology of acute heart failure syndromes. Heart Fail Rev. 2007 Jun;12(2):91–95. doi: 10.1007/s10741-007-9009-2
   PubMed Web of Science ®Google Scholar
• Abraham WT, Adams KF, Fonarow GC, et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the acute decompensated heart failure national registry (adhere). j am coll cardiol. 2005 jul 5;46(1):57–64.
   PubMed Web of Science ®Google Scholar
• Mebazaa A, Motiejunaite J, Gayat E, et al. Long-term safety of intravenous cardiovascular agents in acute heart failure: results from the European society of cardiology heart failure long-term registry. Eur J Heart Fail. 2018 Feb;20(2):332–341.
   PubMed Web of Science ®Google Scholar
• Farmakis D, Parissis J, Papingiotis G, et al. Acute heart failure: epidemiology, classification, and pathophysiology. In: Tubaro M, Vranckx P, and Price S, editors The ESC textbook of intensive and acute cardiovascular care. New York, NY: Oxford University Press; 2015. p. 459–469.
   Google Scholar
• Gamper G, Havel C, Arrich J, et al. Vasopressors for hypotensive shock. Cochrane Database Syst Rev. 2016(2). doi:10.1002/14651858.CD003709.pub4.
   PubMed Web of Science ®Google Scholar
• Schumann J, Henrich EC, Strobl H, et al. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. Cochrane Database Syst Rev. 2018 Jan 29;1(1):Cd009669.
   PubMedGoogle Scholar
• Møller MH, Granholm A, Junttila E, et al. Scandinavian SSAI clinical practice guideline on choice of inotropic agent for patients with acute circulatory failure. Acta Anaesthesiol Scand. 2018;62(4):420–450. doi: 10.1111/aas.13089
   PubMed Web of Science ®Google Scholar
• Levy B, Clere-Jehl R, Legras A, et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol. 2018 Jul 10;72(2):173–182.
   PubMed Web of Science ®Google Scholar
• Crespo-Leiro MG, Barge-Caballero E. Advanced heart failure: definition, epidemiology, and clinical course. Heart Fail Clin. 2021 Oct;17(4):533–545. doi: 10.1016/j.hfc.2021.06.002
   PubMed Web of Science ®Google Scholar
• Ahmad T, Miller PE, McCullough M, et al. Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials. Eur J Heart Fail. 2019 Sep;21(9):1064–1078.
   PubMed Web of Science ®Google Scholar
• Maack C, Eschenhagen T, Hamdani N, et al. Treatments targeting inotropy. Eur Heart J. 2019 Nov 21;40(44):3626–3644.
   PubMed Web of Science ®Google Scholar
• Lannemyr L, Bragadottir G, Redfors B, et al. Effects of milrinone on renal perfusion, filtration and oxygenation in patients with acute heart failure and low cardiac output early after cardiac surgery. J Crit Care. 2020 Jun;57:225–230.
   PubMed Web of Science ®Google Scholar
• Fedele F, Bruno N, Brasolin B, et al. Levosimendan improves renal function in acute decompensated heart failure: possible underlying mechanisms. Eur J Heart Fail. 2014 Mar;16(3):281–288.
   PubMed Web of Science ®Google Scholar
• Theiss HD, Grabmaier U, Kreissl N, et al. Preconditioning with levosimendan before implantation of left ventricular assist devices. Artif Organs. 2014 Mar;38(3):231–234.
   PubMed Web of Science ®Google Scholar
• Khush KK, Hsich E, Potena L, et al. The International thoracic organ transplant registry of the international society for heart and lung transplantation: thirty-eighth adult heart transplantation report - 2021; focus on recipient characteristics. J Heart Lung Transplant. 2021 Oct;40(10):1035–1049.
   PubMedGoogle Scholar
• Crespo-Leiro MG, Metra M, Lund LH, et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018 Nov;20(11):1505–1535.
   PubMed Web of Science ®Google Scholar
• Girerd N, Mewton N, Tartière JM, et al. Practical outpatient management of worsening chronic heart failure. Eur J Heart Fail. 2022 May;24(5):750–761.
   PubMed Web of Science ®Google Scholar
• Assad-Kottner C, Chen D, Jahanyar J, et al. The use of continuous milrinone therapy as bridge to transplant is safe in patients with short waiting times. J Card Fail. 2008 Dec;14(10):839–843.
   PubMed Web of Science ®Google Scholar
• Silva EVC, Ochiai ME, Vieira KRN, et al. The use of peripherally inserted central catheter reduced the incidence of phlebitis in heart failure patients: A randomized trial. J Vasc Access. 2021;11297298211059650.
   Web of Science ®Google Scholar
• García-González MJ, Aldea Perona A, Lara Padron A, et al. Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: the LAICA study. ESC Heart Fail. 2021 Dec;8(6):4820–4831.
   PubMed Web of Science ®Google Scholar
• Pollesello P, Parissis J, Kivikko M, et al. Levosimendan meta-analyses: Is there a pattern in the effect on mortality? Int J Cardiol. 2016 Apr 15;209:77–83.
   PubMed Web of Science ®Google Scholar
• Rafouli-Stergiou P, Parissis JT, Farmakis D, et al. Effects of levosimendan on markers of kidney function in patients with acutely decompensated heart failure and renal impairment. J Cardiovasc Med (Hagerstown). 2017 Oct;18(10):771–773.
   PubMed Web of Science ®Google Scholar
• Tholén M, Ricksten S-E, Lannemyr L. Effects of levosimendan on renal blood flow and glomerular filtration in patients with acute kidney injury after cardiac surgery: a double blind, randomized placebo-controlled study.Crit Care. 2021 [2021 Jun 12];25(1):207. doi: 10.1186/s13054-021-03628-z.
   PubMed Web of Science ®Google Scholar
• Ribeiro Da Silva M, Santos Silva G, Caeiro D, et al. Effects of levosimendan in patients with acute heart failure and cardiorenal syndrome. European Heart Journal Acute Cardiovascular Carequery. 2021;10(Supplement_1). doi: 10.1093/ehjacc/zuab020.028
   Google Scholar
• Pathak A, Lebrin M, Vaccaro A, et al. Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects. J Clin Pharm Therapeutics. 2013;38(5):341–349. doi: 10.1111/jcpt.12067
   PubMed Web of Science ®Google Scholar
• Zemljic G, Anzic Drofenik A, Cerar A, et al. Abstract 15719: levosimendan improves liver function in patients with advanced chronic heart failure. Circulation. 2020;142(Suppl_3):A15719–A15719. doi: 10.1161/circ.142.suppl_3.15719
   Google Scholar
• Bergh CH, Andersson B, Dahlström U, et al. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers. Eur J Heart Fail. 2010 Apr;12(4):404–410.
   PubMed Web of Science ®Google Scholar
• Fowler MB, Alderman EL, Oesterle SN, et al. Dobutamine and dopamine after cardiac surgery: greater augmentation of myocardial blood flow with dobutamine. Circulation. 1984 Sep;70(3 Pt 2):I103–11.
   PubMed Web of Science ®Google Scholar
• Feneck RO, Sherry KM, Withington PS, et al. Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. J Cardiothorac Vasc Anesth. 2001 2001 Jun 1;15(3):306–315. doi: 10.1053/jcan.2001.23274
   PubMed Web of Science ®Google Scholar
• Rathmell JP, Prielipp RC, Butterworth JF, et al. A multicenter, randomized, blind comparison of amrinone with milrinone after elective cardiac surgery. Anesthesia & Analgesia. 1998;86(4):683–690. doi: 10.1097/00000539-199804000-00001
   PubMed Web of Science ®Google Scholar
• Eriksson HI, Jalonen JR, Heikkinen LO, et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Ann Thorac Surg. 2009 Feb;87(2):448–454.
   PubMed Web of Science ®Google Scholar
• Tritapepe L, De Santis V, Vitale D, et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. Br J Anaesth. 2009 Feb;102(2):198–204.
   PubMed Web of Science ®Google Scholar
• Arfaras-Melainis A, Polyzogopoulou E, Triposkiadis F, et al. Heart failure and sepsis: practical recommendations for the optimal management. Heart Fail Rev. 2020 Mar;25(2):183–194.
   PubMed Web of Science ®Google Scholar
• Morelli A, De Castro S, Teboul JL, et al. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive care Med. 2005 May;31(5):638–644.
   PubMed Web of Science ®Google Scholar
• Zangrillo A, Putzu A, Monaco F, et al. Levosimendan reduces mortality in patients with severe sepsis and septic shock: A meta-analysis of randomized trials. J Crit Care. 2015 Oct;30(5):908–913.
   PubMed Web of Science ®Google Scholar
• Jaguszewski MJ, Gasecka A, Hering D, et al. Levosimendan improves the acute course of takotsubo syndrome: a pooled analysis. ESC Heart Fail. 2021 Oct;8(5):4360–4363.
   PubMed Web of Science ®Google Scholar
• Lin Z, von Gise A, Zhou P, et al. Cardiac-specific YAP activation improves cardiac function and survival in an experimental murine MI model. Circ Res. 2014 Jul 18;115(3):354–363.
   PubMed Web of Science ®Google Scholar
• Gabisonia K, Prosdocimo G, Aquaro GD, et al. MicroRNA therapy stimulates uncontrolled cardiac repair after myocardial infarction in pigs. Nature. 2019 May;569(7756):418–422.
   PubMed Web of Science ®Google Scholar
• Lenihan DJ, Anderson SA, Lenneman CG, et al. A phase I, single ascending dose study of cimaglermin alfa (neuregulin 1β3) in patients with systolic dysfunction and heart failure. JACC Basic Transl Sci. 2016 Dec;1(7):576–586.
   PubMedGoogle Scholar
• Paoletti C, Divieto C, Tarricone G, et al. MicroRNA-Mediated direct reprogramming of human adult fibroblasts toward cardiac phenotype. Front Bioeng Biotechnol. 2020;8:529. doi: 10.3389/fbioe.2020.00529
   PubMed Web of Science ®Google Scholar
• Greenberg B, Butler J, Felker GM, et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet. 2016 Mar 19;387(10024):1178–1186.
   PubMed Web of Science ®Google Scholar
• Kieserman JM, Myers VD, Dubey P, et al. Current landscape of heart failure gene therapy. J Am Heart Assoc. 2019 May 21;8(10):e012239.
   PubMed Web of Science ®Google Scholar
• Täubel J, Hauke W, Rump S, et al. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study. Eur Heart J. 2021 Jan 7;42(2):178–188.
   PubMed Web of Science ®Google Scholar
• Reichart D, Newby GA, Wakimoto H, et al. Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice. Nature Med. 2023 2023 Feb 1;29(2):412–421. doi: 10.1038/s41591-022-02190-7
   PubMed Web of Science ®Google Scholar
• Rossinen J, Harjola V-P, Siirilä-Waris K, et al. The use of more than one inotrope in acute heart failure is associated with increased mortality: A multi-centre observational study. Acute Card Care. 2008 2008 Jan 1;10(4):209–213. doi: 10.1080/17482940802262376
   PubMedGoogle Scholar
• Kass DA, Solaro RJ. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation. 2006 Jan 17;113(2):305–315.
   PubMed Web of Science ®Google Scholar
• Francis Gary S, Bartos Jason A, Adatya S. Inotropes.J Am Coll Cardiol. 2014 [2014 May 27];63(20):2069–2078. doi: 10.1016/j.jacc.2014.01.016.
   PubMed Web of Science ®Google Scholar